Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name (Descending) Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
68788-8377-03 68788-8377 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Feb. 28, 2023 In Use
68788-8377-06 68788-8377 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Feb. 28, 2023 In Use
68788-8377-09 68788-8377 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Feb. 28, 2023 In Use
70518-3182-00 70518-3182 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Aug. 5, 2021 In Use
70518-3182-02 70518-3182 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral May 2, 2023 In Use
70518-3600-01 70518-3600 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Dec. 28, 2022 In Use
70518-3600-02 70518-3600 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral March 28, 2023 In Use
70518-3600-03 70518-3600 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral May 1, 2023 In Use
50090-1936-00 50090-1936 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral July 20, 2015 In Use
50090-1936-01 50090-1936 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral July 20, 2015 In Use
50090-1936-02 50090-1936 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Feb. 25, 2022 In Use
63187-0265-10 63187-0265 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Feb. 11, 2022 In Use
63187-0265-30 63187-0265 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Nov. 3, 2014 In Use
63187-0265-60 63187-0265 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral July 3, 2017 In Use
63187-0265-90 63187-0265 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral July 3, 2017 In Use
61919-0733-90 61919-0733 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Jan. 18, 2019 In Use
70518-1704-00 70518-1704 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Nov. 30, 2018 Dec. 2, 2019 In Use
70518-1704-01 70518-1704 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Feb. 19, 2024 In Use
70518-3616-00 70518-3616 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Jan. 18, 2023 In Use
70518-3616-01 70518-3616 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Feb. 10, 2023 In Use
70518-3616-03 70518-3616 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral May 10, 2023 In Use
70518-3616-04 70518-3616 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Jan. 25, 2024 In Use
72189-0542-90 72189-0542 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral March 11, 2024 In Use
54868-2522-00 54868-2522 Filgrastim Neupogen 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous June 8, 1994 In Use
54868-2522-01 54868-2522 Filgrastim Neupogen 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous June 8, 1994 In Use
54868-3050-00 54868-3050 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous Aug. 14, 2006 In Use
54868-5020-00 54868-5020 Filgrastim Neupogen 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous March 11, 2004 In Use
55513-0209-01 55513-0209 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0209-10 55513-0209 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0209-91 55513-0209 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0530-01 55513-0530 Filgrastim Neupogen 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous May 19, 1997 In Use
55513-0530-10 55513-0530 Filgrastim Neupogen 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous May 19, 1997 In Use
55513-0546-01 55513-0546 Filgrastim Neupogen 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous April 7, 1997 In Use
55513-0546-10 55513-0546 Filgrastim Neupogen 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous April 7, 1997 In Use
55513-0924-01 55513-0924 Filgrastim Neupogen 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0924-10 55513-0924 Filgrastim Neupogen 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0924-91 55513-0924 Filgrastim Neupogen 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
70121-1569-07 70121-1569 Filgrastim RELEUKO 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
70121-1571-07 70121-1571 Filgrastim RELEUKO 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
70121-1568-07 70121-1568 Filgrastim RELEUKO 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
70121-1568-01 70121-1568 Filgrastim RELEUKO 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
70121-1570-07 70121-1570 Filgrastim RELEUKO 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
70121-1570-01 70121-1570 Filgrastim RELEUKO 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb. 25, 2022 In Use
59572-0720-12 59572-0720 Fedratinib Hydrochloride Inrebic 100.0 mg/1 Chemotherapy Enzyme Inhibitor JAK2, FLT3 Oral Aug. 16, 2019 In Use
64842-0120-04 64842-0120 FUTIBATINIB LYTGOBI 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral Feb. 3, 2023 In Use
64842-0120-05 64842-0120 FUTIBATINIB LYTGOBI 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral Feb. 3, 2023 In Use
64842-0120-06 64842-0120 FUTIBATINIB LYTGOBI 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral Feb. 3, 2023 In Use
00143-9384-01 00143-9384 FOSAPREPITANT DIMEGLUMINE FOSAPREPITANT DIMEGLUMINE 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 8, 2020 In Use
00143-9428-01 00143-9428 FOSAPREPITANT DIMEGLUMINE FOSAPREPITANT DIMEGLUMINE 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous May 1, 2021 In Use
82238-0018-01 82238-0018 FOSAPREPITANT DIMEGLUMINE FOSAPREPITANT DIMEGLUMINE 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jan. 12, 2021 In Use
70625-0311-01 70625-0311 FOSAPREPITANT FOSAPREPITANT 150.0 mg/mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Nov. 3, 2021 In Use
16729-0240-03 16729-0240 FOSAPREPITANT Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Oct. 22, 2020 In Use
81952-0911-01 81952-0911 FOSAPREPITANT FOSAPREPITANT 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous July 14, 2023 In Use
82243-1001-01 82243-1001 FOSAPREPITANT FOCINVEZ 150.0 mg/50mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Aug. 30, 2023 In Use
51862-0362-40 51862-0362 FLUOROURACIL FLUOROURACIL 50.0 mg/g Chemotherapy Antimetabolite Pyrimidine Analog Topical Dec. 3, 2019 In Use
50742-0423-10 50742-0423 FLUOROURACIL FLUOROURACIL 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
50742-0481-20 50742-0481 FLUOROURACIL FLUOROURACIL 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
16729-0131-30 16729-0131 FLUDARABINE FLUDARABINE PHOSPHATE 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Nov. 22, 2022 In Use
78206-0153-01 78206-0153 FINASTERIDE PROSCAR 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral June 1, 2021 In Use
78206-0153-02 78206-0153 FINASTERIDE PROSCAR 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral June 1, 2021 In Use
00009-7663-04 00009-7663 Exemestane Aromasin 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Oct. 21, 1999 In Use
00054-0080-13 00054-0080 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral April 1, 2011 In Use
00832-0595-30 00832-0595 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral July 27, 2017 In Use
54868-5261-00 54868-5261 Exemestane Aromasin 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral June 29, 2005 In Use
59762-2858-01 59762-2858 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral April 1, 2011 In Use
60687-0132-11 60687-0132 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral March 31, 2015 April 30, 2017 No Longer Used
60687-0132-21 60687-0132 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Dec. 22, 2015 April 30, 2017 No Longer Used
70771-1374-03 70771-1374 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Oct. 8, 2018 In Use
68382-0383-06 68382-0383 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Oct. 8, 2018 In Use
65162-0240-03 65162-0240 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Dec. 29, 2018 In Use
63629-2056-01 63629-2056 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Dec. 19, 2019 In Use
47781-0108-30 47781-0108 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral July 25, 2014 Dec. 1, 2022 No Longer Used
51991-0005-33 51991-0005 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Dec. 19, 2019 Dec. 31, 2022 In Use
51991-0005-90 51991-0005 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Nov. 15, 2020 In Use
00378-5001-93 00378-5001 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral March 10, 2017 April 30, 2023 No Longer Used
71921-0190-33 71921-0190 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Jan. 15, 2021 In Use
59651-0516-30 59651-0516 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral May 20, 2022 In Use
00093-7766-24 00093-7766 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 10, 2020 In Use
00093-7767-24 00093-7767 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 10, 2020 In Use
00093-7768-24 00093-7768 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 10, 2020 In Use
00054-0480-13 00054-0480 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Feb. 12, 2021 In Use
00054-0480-14 00054-0480 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2020 In Use
00054-0481-13 00054-0481 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Feb. 12, 2021 In Use
00054-0481-14 00054-0481 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2020 In Use
00054-0497-13 00054-0497 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Feb. 12, 2021 In Use
00054-0497-14 00054-0497 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2020 In Use
00378-0005-85 00378-0005 Everolimus Everolimus 2.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
00378-0006-85 00378-0006 Everolimus Everolimus 3.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
00378-0007-85 00378-0007 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
00054-0482-13 00054-0482 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Dec. 7, 2021 In Use
49884-0128-91 49884-0128 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Nov. 29, 2022 In Use
00378-3096-85 00378-3096 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Dec. 15, 2022 In Use
00378-3098-85 00378-3098 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Dec. 15, 2022 In Use
00378-3099-85 00378-3099 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Dec. 15, 2022 In Use
00078-0566-51 00078-0566 Everolimus Afinitor 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 31, 2009 In Use
00078-0566-61 00078-0566 Everolimus Afinitor 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 22, 2010 In Use
00078-0567-51 00078-0567 Everolimus Afinitor 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 31, 2009 In Use
00078-0567-61 00078-0567 Everolimus Afinitor 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral March 22, 2010 In Use
00078-0594-51 00078-0594 Everolimus Afinitor 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral July 9, 2010 In Use
00078-0594-61 00078-0594 Everolimus Afinitor 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral July 9, 2010 In Use

Found 10,000 results in 14 milliseconds — Export these results